Dec07Mon

Member News from ICON Clinical Research

ICON Acquires PMG Research Inc.

Acquisition enhances ICON’s site and patient engagement capabilities

Dublin, Ireland, 7th December, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the acquisition of PMG Research, Inc., an integrated network of clinical research sites operating from 12 metropolitan areas throughout the US. The acquisition will enhance ICON’s ability to access and engage with investigator sites and patients, helping customers to reduce the overall time and cost associated with drug development. 

PMG Research is an integrated network of clinical research facilities in the US. The acquisition will enhance ICON’s ability to enrol and engage patients in clinical trials. Identifying, enrolling and engaging patients to participate in clinical trials is a key challenge within the drug development industry and can represent more than 30% of the total costs of developing a drug. By owning a network of clinical research facilities, ICON will be able to help customers to improve their patient enrolment timelines, while at the same time will offer patients access to a broader range of care options.

PMG Research is ICON’s second acquisition this year. It follows our acquisition of MediMedia Pharma Solutions in March.

To read more, please click HERE.

Leave a Reply